Martina Balestri1, Raffaella Calati2, Daniel Souery3, Alexander Kautzky4, Siegfried Kasper4, Stuart Montgomery5, Joseph Zohar6, Julien Mendlewicz7, Alessandro Serretti8. 1. Department of Biomedical and NeuroMotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123 Bologna, Italy. 2. INSERM U1061, University of Montpellier, FondaMental Foundation, Montpellier, France. 3. Laboratoire de Psychologie Médicale, Université Libre de Bruxelles, and Centre Européen de Psychologie Médicale-PsyPluriel, Brussels, Belgium. 4. Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria. 5. University of London, Imperial College, London, United Kingdom. 6. Chaim Sheba Medical Center, Chaim Sheba Medical Center, Tel-Hashomer, Israel. 7. Université Libre de Bruxelles, Brussels, Belgium. 8. Department of Biomedical and NeuroMotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123 Bologna, Italy. Electronic address: alessandro.serretti@unibo.it.
Abstract
BACKGROUND: Few studies investigated socio-demographic and clinical predictors of non response and remission in treatment resistant depression (TRD) in the case of failure of more than two adequate antidepressant (AD) trial. The primary aim of this study was to investigate socio-demographic and clinical predictors of TRD defined as the lack of response to at least three adequate AD treatments, two of which prospectively evaluated. As secondary aims, we also investigated predictors of non response and remission to: (1) at least two adequate AD treatment (one of which prospectively assessed); (2) at least one adequate and retrospectively assessed AD treatment. METHODS: In the context of a European multicenter project, 407 major depressive disorder (MDD) patients who failed to respond to a previous AD treatment were recruited for a 2 stage trial, firstly receiving venlafaxine and then escitalopram. MINI, HRSD, MADRS, UKU, CGI-S and CGI-I were administered. RESULTS: Ninety eight subjects (27.61%) were considered as resistant to three AD treatments. Clinical predictors were: longer duration and higher severity of the current episode (p=0.004; ES=0.24; p=0.01; RR=1.41, respectively), outpatient status (p=0.04; RR=1.58), higher suicidal risk level (p=0.02; RR=1.49), higher rate of the first/second degree psychiatric antecedents (MDD and others) (p=0.04; RR=1.31, p=0.03; RR=1.32 respectively) and side effects during treatments (p=0.002; RR=2.82). Multivariate analyses underlined the association between TRD and the severity of the current episode (p=0.04). As for secondary outcomes, predicting factors were partially overlapping. LIMITATIONS: The limited sample size and specific drugs used limit present findings. CONCLUSION: Subjects with a high degree of resistance to AD treatments show specific features which may guide the clinicians to the choice of more appropriate therapies at baseline.
BACKGROUND: Few studies investigated socio-demographic and clinical predictors of non response and remission in treatment resistant depression (TRD) in the case of failure of more than two adequate antidepressant (AD) trial. The primary aim of this study was to investigate socio-demographic and clinical predictors of TRD defined as the lack of response to at least three adequate AD treatments, two of which prospectively evaluated. As secondary aims, we also investigated predictors of non response and remission to: (1) at least two adequate AD treatment (one of which prospectively assessed); (2) at least one adequate and retrospectively assessed AD treatment. METHODS: In the context of a European multicenter project, 407 major depressive disorder (MDD) patients who failed to respond to a previous AD treatment were recruited for a 2 stage trial, firstly receiving venlafaxine and then escitalopram. MINI, HRSD, MADRS, UKU, CGI-S and CGI-I were administered. RESULTS: Ninety eight subjects (27.61%) were considered as resistant to three AD treatments. Clinical predictors were: longer duration and higher severity of the current episode (p=0.004; ES=0.24; p=0.01; RR=1.41, respectively), outpatient status (p=0.04; RR=1.58), higher suicidal risk level (p=0.02; RR=1.49), higher rate of the first/second degree psychiatric antecedents (MDD and others) (p=0.04; RR=1.31, p=0.03; RR=1.32 respectively) and side effects during treatments (p=0.002; RR=2.82). Multivariate analyses underlined the association between TRD and the severity of the current episode (p=0.04). As for secondary outcomes, predicting factors were partially overlapping. LIMITATIONS: The limited sample size and specific drugs used limit present findings. CONCLUSION: Subjects with a high degree of resistance to AD treatments show specific features which may guide the clinicians to the choice of more appropriate therapies at baseline.
Authors: Yasmina M Saade; Ginger Nicol; Eric J Lenze; J Philip Miller; Michael Yingling; Julie Loebach Wetherell; Charles F Reynolds; Benoit H Mulsant Journal: Depress Anxiety Date: 2019-11-04 Impact factor: 6.505
Authors: Mahmoud S Abdallah; Esraa M Mosalam; Abdel-Aziz A Zidan; Khaled S Elattar; Shimaa A Zaki; Ahmed N Ramadan; Abla M Ebeid Journal: Neurotherapeutics Date: 2020-10 Impact factor: 6.088
Authors: Christine Tara Peterson; Sarah M Bauer; Deepak Chopra; Paul J Mills; Raj K Maturi Journal: J Evid Based Complementary Altern Med Date: 2017-09-22
Authors: Heidi Taipale; Johan Reutfors; Antti Tanskanen; Lena Brandt; Jari Tiihonen; Allitia DiBernardo; Ellenor Mittendorfer-Rutz; Philip Brenner Journal: BMC Psychiatry Date: 2020-05-13 Impact factor: 3.630
Authors: Nicolas A Nuñez; Stefano Comai; Eduard Dumitrescu; Maykel F Ghabrash; John Tabaka; Marie Saint-Laurent; Stephen Vida; Theodore Kolivakis; Allan Fielding; Nancy Low; Pablo Cervantes; Linda Booij; Gabriella Gobbi Journal: BMC Psychiatry Date: 2018-03-16 Impact factor: 3.630
Authors: A Kautzky; M Dold; L Bartova; M Spies; G S Kranz; D Souery; S Montgomery; J Mendlewicz; J Zohar; C Fabbri; A Serretti; R Lanzenberger; D Dikeos; D Rujescu; S Kasper Journal: Acta Psychiatr Scand Date: 2018-10-05 Impact factor: 6.392